The Australian Immunisation Handbook 10th Edition 2013

• A table (Table 4.16.1) summarising World Health Organization (WHO)
categories of lyssavirus exposure, for guidance in use of post-exposure
prophylaxis, has been added.
• Algorithms are provided with details of the recommended management
pathways for post-exposure prophylaxis for rabies and other lyssaviruses
(including Australian bat lyssavirus), and for booster doses for persons at
ongoing risk of exposure to rabies and other lyssaviruses.
• Advice regarding the completion of post-exposure prophylaxis commenced
overseas has been expanded, including the addition of a summary table
(Table 4.16.2).
• Persons who have completed a primary course of a currently available cell
culture-derived rabies vaccine no longer routinely require booster doses if
travelling or living in an area of high risk.
• Information on the role of serological testing has been more clearly presented.
4.17 Rotavirus
• The upper age limits for each dose of rotavirus vaccines are more clearly
defined.
• Contraindications to rotavirus vaccination now include previous history of
intussusception (IS) and severe combined immunodeficiency in infants.
• Information on the safety of rotavirus vaccines in infants with underlying
conditions and infants who are immunocompromised has been updated.
• Information on adverse events following rotavirus vaccination has been
updated and expanded, including new information on the low, but increased,
risk of IS occurring following the 1st or 2nd dose of either rotavirus vaccine.
4.20 Tuberculosis
• Bacille Calmette-Guérin (BCG) vaccination is no longer routinely
recommended for neonates weighing